ClinicalTrials.gg
RecruitingNCT06192979Updated Jul 7, 2026

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

An interventional study of Daratumumab and Bortezomib in Amyloidosis; Systemic and AL Amyloidosis, sponsored by Jin Lu, MD. Recruiting at 7 sites in China. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Jin Lu, MD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing bortezomib in Immunoglobulin Light-chain Amyloidosis — 4 open to participants now, 4 under way, 1 of them phase 3. Bortezomib · Immunoglobulin Light-chain Amyloidosis.

Planned enrollment
3rd of 13
41 · median 40
Started
2024
with 2 others
No phase
Only one
of the 14
Registered
12th of 14
by date
Lead sponsor
2 of 14
Jin Lu, MD

Among the 14 studies testing bortezomib in Immunoglobulin Light-chain Amyloidosis, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is the only one with no phase, and was the 12th registered.

Immunoglobulin Light-chain Amyloidosis

239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.

Browse Immunoglobulin Light-chain Amyloidosis studies →

Open to participants now

4 of the 14 studies testing bortezomib in Immunoglobulin Light-chain Amyloidosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bortezomib in Immunoglobulin Light-chain Amyloidosis, or all of them as a file.
02

Study summary

Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%. Considering that Bcl-2 inhibitor is effective for AL amyloidosis with t(11; 14) and the median hematologic onset time of DBD is 7 days. We design a a prospective study on AL amyloidosis with t(11; 14). All patients receive DBD at the beginning. Patient will receive DBD for at least 6 cycles if achieve rapid hematologic response at day 7, while other patients will receive daratumumab, venetoclax and dexamethasone.

Read the detailed description

The goal of this clinical trial is to optimize the first line treatment for systemic AL amyloidosis with t(11;14). The aim of this study is to pursue early complete hematologic response. The primary endpoint is overall complete hematologic response (CHR) rate at 6 months. Participants will be treated according to the hematologic response after 7 days. If the patient get rapid response after 7 days, he/she will receive daratumumab, venetoclax and dexamethasone (DBD) for at least 6 cycles. If the patient do not get rapid response, he/she will receive daratumumab, venetoclax and dexamethasone.

03

Conditions studied

  • Amyloidosis; Systemic
  • AL Amyloidosis

Keywords

  • t(11;14)
  • Rapid Response
  • AL amyloidosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of systemic AL amyloidosis;
  2. Daratumumab, bortezomib, dexamethasone used in treatment;
  3. greater than 12 weeks;
  4. HGB ≥70g/L;
  5. Blood oxygen saturation >90%;
  6. Total (TBil) ≤3× (ULN); (AST) and alanine aminotransferase (ALT) ≤3.0×ULN;
  7. explained to, understood by and signed by the patient.

Exclusion criteria

Exclusion Criteria:

  1. Fulfill with the criteria of active multiple myeloma or active lymphoplasmacytic lymphoma.
  2. Presence of other tumors which is/are in advanced malignant stage and has/have systemic ;
  3. Severe or persistent infection that cannot be effectively controlled;
  4. Presence of severe diseases or immunodeficiency disease;
  5. Patients with active or ([HBVDNA+] or [HCVRNA+]);
  6. Patients with infection or syphilis infection;
  7. Any situations that the researchers believe will increase the risks for the subject or affect the results of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Other
    Rapid Response Group

    Daratumumab, bortezomib, dexamethasone

    Drug: Daratumumab · Drug: Bortezomib · Drug: Dexamethasone

  • Other
    Non-Rapid Response Group

    Daratumumab, venetoclax, dexamethasone

    Drug: Daratumumab · Drug: Dexamethasone · Drug: Venetoclax

Interventions

  • Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles. Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice.

  • All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.

  • All patients received 20-40 mg oral or intravenous dexamethasone

  • All patients received venetoclax 400mg daily.

06

What researchers measure

Primary outcomes

  1. Overall CHR rate at 6 months

    Overall complete hematologic response rate at 6 months

    Time frame: Overall CHR rate at 6 months

Secondary outcomes

  1. Cardiac response at 6 months

    Cardiac response at 6 months

    Time frame: Cardiac response at 6 months

  2. Renal response at 6 months

    Renal response at 6 months

    Time frame: Renal response at 6 months

  3. Hepatic response at 6 months

    Hepatic response at 6 months

    Time frame: Hepatic response at 6 months

  4. Estimated 2-year PFS

    Estimated 2-year progression free survival

    Time frame: Estimated 2-year PFS

  5. Estimated 2-year OS

    Estimated 2-year overall survival

    Time frame: Estimated 2-year overall survival

  6. MRD status at 6 months

    Minimal residual disease status at 6 months

    Time frame: MRD status at 6 months

  7. TRAEs

    treatment-related adverse events up to 6 months

    Time frame: TRAEs

07

Study locations

7 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Sep 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Jan 5, 2024
StartActual
Jan 5, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Mar 31, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06192979
Lead sponsor
Jin Lu, MD
Responsible party
Jin Lu, MD (Principal Investigator, Peking University People's Hospital) — Sponsor-investigator
First posted
Jan 5, 2024
Start date
Jan 5, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Jin Lu
Contact
jin1lu@sina.com
+8613311491805
Jin Lu
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Venetoclax

Start the discussion